Results 271 to 280 of about 216,066 (333)

Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential. [PDF]

Bone Rep
Ursachi VC, Horak J, Fafilek B.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2018
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema, Zebda, Amy S, Paller
openaire   +3 more sources

Advances in the development of phosphodiesterase-4 inhibitors.

Journal of Medicinal Chemistry, 2020
Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the
Ting Peng, B. Qi, Jun He, H. Ke, Jianyou Shi   +4 more
semanticscholar   +1 more source

Phosphodiesterase in Psoriasis

British Journal of Dermatology, 1969
SUMMARY. . Phosphodiesterase activity was determined by a fluorometric method using thymidine-5′-3–0-methoxy fluorescein phosphate as a substrate, in blood serum, finger-blood, normal skin, foreskin and psoriatic skin. Higher enzyme activity was found in psoriasis both in blood-serum and finger-blood in comparison with normal controls ...
F, Zaruba, M A, Karasek, E M, Farber
openaire   +2 more sources

Phosphodiesterase-5 Inhibitors

2013
Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire   +2 more sources

Lung Phosphodiesterase Isoenzymes

1993
The distinct phosphodiesterase isoenzyme activities in guinea-pig lung were identified and characterised. We demonstrate that protein kinase A catalyses the activation of lung Type V cyclic GMP phosphodiesterase. This occurs via a marked change in the Vmax for cyclic GMP hydrolysis.
Pyne, N J, Burns, F
openaire   +2 more sources

Cyclic nucleotide phosphodiesterases

Journal of Allergy and Clinical Immunology, 2001
Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led
openaire   +2 more sources

Tyrosyl‐DNA Phosphodiesterase (Tdp1) (3′‐Phosphotyrosyl DNA Phosphodiesterase)

2006
Tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds in vitro. Because topoisomerase I, a type IB topoisomerase, is the only enzyme known to form 3'-phosphotyrosine bonds in eukaryotic cells, it was proposed that Tdp1 is involved in the repair of dead-end topoisomerase I-DNA covalent complexes that may form in vivo.
Amy C, Raymond, Alex B, Burgin
openaire   +2 more sources

Phosphodiesterase fromThiobacillus thioparus

Experientia, 1961
La phosphodiesterase a ete isolee des cellules duTh. thioparus et partiellement purifiee. Cette enzyme hydrolise les polynucleotides jusqu'a 5′-mononucleotides. Elle est specifiquement activee par les ions du Mn++ et inhibee par les ions du Zn++. Son pH optimum est compris entre 8,5–9,0.
openaire   +2 more sources